176 related articles for article (PubMed ID: 37294584)
21. Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018.
Lakdawalla D; Li M
JAMA Netw Open; 2021 May; 4(5):e219030. PubMed ID: 33950205
[TBL] [Abstract][Full Text] [Related]
22. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
23. Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018.
Yeung K; Dusetzina SB; Basu A
JAMA Netw Open; 2021 Jun; 4(6):e2113393. PubMed ID: 34125219
[TBL] [Abstract][Full Text] [Related]
24. Inflationary Rebates For Generic Drugs Sold Through Medicaid Saved Billions During 2017-20.
Rome BN; Patel AN; Kesselheim AS
Health Aff (Millwood); 2023 Jun; 42(6):770-778. PubMed ID: 37276474
[TBL] [Abstract][Full Text] [Related]
25. Projected spending for brand-name drugs in English primary care given US prices: a cross-sectional study.
Liu M; MacKenna B; Feldman WB; Walker AJ; Avorn J; Kesselheim AS; Goldacre B
J R Soc Med; 2020 Sep; 113(9):350-359. PubMed ID: 32910868
[TBL] [Abstract][Full Text] [Related]
26. The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies.
Kakani P; Chernew M; Chandra A
J Health Polit Policy Law; 2022 Dec; 47(6):629-648. PubMed ID: 35867538
[TBL] [Abstract][Full Text] [Related]
27. Changes in Retail Prices of Prescription Dermatologic Drugs From 2009 to 2015.
Rosenberg ME; Rosenberg SP
JAMA Dermatol; 2016 Feb; 152(2):158-63. PubMed ID: 26606197
[TBL] [Abstract][Full Text] [Related]
28. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
29. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
30. Spending on and Use of Clinician-Administered Drugs in Medicare.
Hyland MF; Sachs RM; Robillard L; Hayford TB; Bai G
JAMA Health Forum; 2023 Sep; 4(9):e232941. PubMed ID: 37682554
[TBL] [Abstract][Full Text] [Related]
31. Factors Associated With Prescriptions for Branded Medications in the Medicare Part D Program.
Socal MP; Bai G; Anderson GF
JAMA Netw Open; 2021 Mar; 4(3):e210483. PubMed ID: 33651110
[TBL] [Abstract][Full Text] [Related]
32. Trends and determinants of retail prescription drug costs.
Teasdale B; Nguyen A; van Meijgaard J; Schulman KA
Health Serv Res; 2022 Jun; 57(3):548-556. PubMed ID: 35211965
[TBL] [Abstract][Full Text] [Related]
33. Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition.
Michaeli DT; Michaeli T
Pharmacoeconomics; 2024 Jan; 42(1):117-131. PubMed ID: 37855850
[TBL] [Abstract][Full Text] [Related]
34. Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone.
Rome BN; Egilman AC; Patel NG; Kesselheim AS
Value Health; 2023 Mar; 26(3):370-377. PubMed ID: 36266218
[TBL] [Abstract][Full Text] [Related]
35. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011.
Cheng N; Banerjee T; Qian J; Hansen RA
J Am Pharm Assoc (2003); 2017; 57(3):341-348. PubMed ID: 28400255
[TBL] [Abstract][Full Text] [Related]
36. Generic Drug Price Hikes And Out-Of-Pocket Spending For Medicare Beneficiaries.
Joyce G; Henkhaus LE; Gascue L; Zissimopoulos J
Health Aff (Millwood); 2018 Oct; 37(10):1578-1586. PubMed ID: 30273018
[TBL] [Abstract][Full Text] [Related]
37. Drug rebates in Medicare Part D: Excess patient costs in the case of hepatitis C treatments.
Arambadjis Y; Butler M; Huckfeldt P; Schondelmeyer S
Res Social Adm Pharm; 2020 Sep; 16(9):1290-1293. PubMed ID: 31147206
[TBL] [Abstract][Full Text] [Related]
38. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
[TBL] [Abstract][Full Text] [Related]
39. Characteristics and Price Increases Among Sole-Source, Off-Patent Drugs in the United States, 2008 to 2018.
Alpern JD; Shahriar AA; Xi M; Thapa S; Kodet AJ; Stauffer WM; Vazquez Benitez G; Pawloski PA; Dehmer SP
JAMA Netw Open; 2020 Aug; 3(8):e2013595. PubMed ID: 32804216
[TBL] [Abstract][Full Text] [Related]
40. What do pharmaceuticals really cost in the long run?
Lakdawalla D; MacEwan JP; Dubois R; Westrich K; Berdud M; Towse A
Am J Manag Care; 2017 Aug; 23(8):488-493. PubMed ID: 29087143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
